• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aprea Therapeutics Inc (NQ: APRE )

    3.550 +0.040 (+1.14%)
    Streaming Delayed Price Updated: 3:51 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 9,591
    Open 3.500
    Bid (Size) 3.250 (5)
    Ask (Size) 3.860 (12)
    Prev. Close 3.510
    Today's Range 3.490 - 3.690
    52wk Range 3.200 - 8.847
    Shares Outstanding 5,431,903
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
    APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Aprea Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    -29.00%
    -29.00%
    1 Month
    -10.35%
    -10.35%
    3 Month
    -31.60%
    -31.60%
    6 Month
    -50.35%
    -50.35%
    1 Year
    -2.76%
    -2.76%

    More News

    Read More
    Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
    From Aprea Therapeutics
    Via GlobeNewswire
    APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
    From Aprea Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
    From Aprea Therapeutics
    Via GlobeNewswire
    Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
    From Aprea Therapeutics
    Via GlobeNewswire
    Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
    From Aprea Therapeutics
    Via GlobeNewswire
    A Look Into Healthcare Sector Value Stocks
    Via Benzinga
    Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
    From Aprea Therapeutics
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.